Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?

Affiliations

¹ Medical Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA. Electronic address: daniel.geynisman@fccc.edu.
² Medical Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA.

Editorial

Daniel M Geynisman et al. Eur Urol. 2016 Dec.

. 2016 Dec;70(6):971-973.

doi: 10.1016/j.eururo.2016.05.026. Epub 2016 May 26.

¹ Medical Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA. Electronic address: daniel.geynisman@fccc.edu.
² Medical Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA.

No abstract available

Comment on

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE. Smith MR, et al. Eur Urol. 2016 Dec;70(6):963-970. doi: 10.1016/j.eururo.2016.04.023. Epub 2016 May 6. Eur Urol. 2016. PMID: 27160947 Free PMC article. Clinical Trial.